Patients and healthcare professionals may possibly have concerns about oral bisphosphonate medications and atypical subtrochanteric femur fractures &ndash fractures in the bone just beneath the hip joint. Oral bisphosphonates are typically prescribed to stop or treat osteoporosis in postmenopausal girls. Typical brand names of medicines in this class contain Fosamax, Actonel, Boniva, and Reclast. If you have taken fosamax you should speak to your health care provider to see if you are at risk for a fosamax femur fracture.

Latest news reports have raised the question about no matter whether there is an elevated danger of this sort of fracture in patients with osteoporosis making use of these medications. At this point, the information that FDA has reviewed have not shown a clear connection between bisphosphonate use and a danger of atypical subtrochanteric femur fractures. FDA is operating closely with outside authorities, including members of the not too long ago convened American Society of Bone and Mineral Analysis Subtrochanteric Femoral Fracture Process Force, to gather extra information that might offer much more insight into this problem.

Based on published case reports of atypical subtrochanteric femur fractures occurring in females with osteoporosis using bisphosphonates, FDA, in June 2008, requested details from all bisphosphonate drug manufacturers with regards to this possible safety signal. All obtainable case reports and clinical trial information were requested. FDA’s assessment of these information did not show an boost in this risk in women employing these medications.

In addition, FDA reviewed a December 2008 write-up in the Journal of Bone and Mineral Investigation by Abrahamsen et al¹, that analyzed information from two big observational scientific studies in patients with osteoporosis. The authors concluded that atypical subtrochanteric femur fractures had several comparable capabilities in common with classical osteoporotic hip fractures, including patient age, gender, and trauma mechanism. The information showed that patients taking bisphosphonates and those not taking bisphosphonates had related numbers of atypical subtrochanteric femur fractures relative to classical osteoporotic hip fractures. If you or someone you know has suffered a femur fracture after taking Fosamax, you or they may be eligible for a fosamax femur fracture lawsuit.

This communication is in keeping with FDA’s commitment to inform the public about its ongoing safety review of drugs. The agency will continue to review new details as it becomes accessible and will update the public when the agency’s evaluation is total.

Healthcare specialists should continue to follow the suggestions in the drug label when prescribing oral bisphosphonates. Patients must not cease taking their medication unless told to do so by their healthcare specialist. Patients must speak to their healthcare expert about any concerns they have with these medications.

Tags: fosamax femur fracture lawsuit, fosamax femure fracture